Vivek Ramaswamy is the Founder and Executive Chairman of Roivant Sciences. Roivant is focused on developing transformative medicines faster by building technologies and deploying talent in creative ways and has developed over 40 medicines in multiple disease areas. Mr. Ramaswamy graduated summa cum laude in Biology from Harvard University in 2007 and began his career as a successful biotech investor where he oversaw investment in numerous companies, including those that helped develop curative treatment regimens for hepatitis C virus. He continued to work as an investor while earning his law degree from Yale Law School, where he was a Paul & Daisy Soros Fellow.

He is a frequent op-ed contributor to publications including The Wall Street Journal, Newsweek, and National Review, and his forthcoming book Woke, Inc. will be published by Hachette Book Group in August.